<SEC-DOCUMENT>0001178913-22-002928.txt : 20220804
<SEC-HEADER>0001178913-22-002928.hdr.sgml : 20220804
<ACCEPTANCE-DATETIME>20220804073020
ACCESSION NUMBER:		0001178913-22-002928
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220804
FILED AS OF DATE:		20220804
DATE AS OF CHANGE:		20220804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		221134696

	BUSINESS ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2228217.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using Broadridge PROfile 22.7.2.5063
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">Form 6-K</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">For the month of August 2022</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Commission File Number 000-30902</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">COMPUGEN LTD.</div>
      <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
      <table cellspacing="0" cellpadding="0" id="zaa88e716626d4721b4434f0ece5a2dae" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 100%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">26&#160;Harokmim Street</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Holon 5885849, Israel</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">(Address of Principal Executive Offices)&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:<br>
        <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Form 20-F&#160; &#9746; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F&#160; &#9744;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#160; &#160; &#160; &#160; &#9744;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#160; &#160; &#160; &#160; &#9744;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Compugen Ltd.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">On or about August 4, 2022, Compugen Ltd. (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) took actions to distribute copies of its proxy statement to
            its shareholders and to mail to its shareholders of record a proxy statement for an Annual General Meeting of Shareholders to be held on Wednesday, September 14, 2022, at 5:00 PM (Israel time) in Israel.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">A copy of the notice of 2022 annual general meeting of
            shareholders of the Company, proxy statement and proxy card are attached to this Form 6-K as Exhibit 99.1.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">The information contained in this Form 6-K is hereby incorporated by reference into the Company&#8217;s Registration Statements on Form F-3,
          File No.&#160;333-240183.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Exhibits</div>
      <div style="line-height: 1.25; font-weight: bold;">Exhibit</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="5c13967c08f64ea2a56c12451d16829b" class="DSPFListTable">

          <tr>
            <td style="width: 72pt; vertical-align: top; align: right;"><font style="font-weight: bold;"><u>Number</u></font></td>
            <td style="width: auto; vertical-align: top;"><font style="font-weight: bold;"><u>Description of Exhibit</u></font></td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" id="z7b1cd4f73d8d431ca8476f6f553344db" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 72pt; vertical-align: top; align: right;"><a href="exhibit_99-1.htm">99.1</a></td>
              <td style="width: auto; vertical-align: top;">
                <div><a href="exhibit_99-1.htm">Notice of 2022 annual general meeting of shareholders of
                    Compugen Ltd., proxy statement and proxy card.</a></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Signatures</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
        behalf by the undersigned thereunto duly authorized.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z327db62c356e43efbc3c6012669a973c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="vertical-align: bottom;" colspan="3">
              <div style="line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: middle;" colspan="4">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Date: August 4, 2022</div>
            </td>
            <td style="width: 3%; vertical-align: bottom;">
              <div style="line-height: 1.25;">By:&#160;</div>
            </td>
            <td style="width: 35%; vertical-align: bottom;">
              <div style="line-height: 1.25;"><u>/s/ Eran Ben Dor
                    <br>
                  </u></div>
            </td>
            <td style="width: 12%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 35%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Eran Ben Dor</div>
              <div style="line-height: 1.25;">General Counsel</div>
            </td>
            <td style="width: 12%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using Broadridge PROfile 22.7.2.5063
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <u><font style="font-weight: bold;">Exhibit 99.1</font></u><br>
    </div>
    <div>
      <div id="DSPFPageHeader">
        <div style="line-height: 1.25; text-align: center;"><img src="image00001.jpg"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: right; line-height: 1.25;">August 4, 2022</div>
      <div style="line-height: 1.25">&#160; <br>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Dear Shareholder,</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">You are cordially invited to attend, and notice is hereby given of, the 2022 Annual General Meeting of Shareholders of Compugen Ltd. (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) to be
        held at the Company&#8217;s offices at 26 Harokmim Street, Bldg. D, Holon, Israel, on Wednesday, September 14, 2022, at 5:00 PM (Israel time) (the &#8220;<font style="font-weight: bold;">Meeting</font>&#8221;) for the following purposes:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb44d392b651b44e3b5833ed123899d8d">

          <tr>
            <td style="width: 21.3pt;"><br>
            </td>
            <td style="width: 14.15pt; vertical-align: top; align: right;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To re-elect seven (7) directors to serve as members of the Board of Directors of the Company (the &#8220;<font style="font-weight: bold;">Board of Directors</font>&#8221;);</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za6da2d56577849d683e0a84e6bc7a334">

          <tr>
            <td style="width: 21.3pt;"><br>
            </td>
            <td style="width: 14.15pt; vertical-align: top; align: right;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To re-appoint Kost Forer Gabbay &amp; Kasierer (a member of Ernst &amp; Young Global), as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2022, and until the next annual general
                meeting of the Company&#8217;s shareholders, and to authorize the Board of Directors, upon recommendation of the Company&#8217;s Audit Committee, to determine the remuneration thereof in accordance with the volume and nature of its services.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">In addition, at the Meeting, shareholders will also have an opportunity to discuss the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2021; this
        item will not involve a vote of the shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Should changes be made to any item on the agenda for the Meeting after the publication of this proxy statement, the Company will communicate the changes to its shareholders through the publication
        of a press release, a copy of which will be filed with the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold;">SEC</font>&#8221;) on a Report on Form 6-K and with the Israeli Securities Authority (the &#8220;<font style="font-weight: bold;">ISA</font>&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Only shareholders of record at the close of business day on Tuesday, August 9, 2022, the record date for determining those shareholders eligible to vote at the Meeting, are entitled to vote at the
        Meeting and at any postponements or adjournments thereof. All such shareholders are cordially invited to attend the Meeting in person.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">We currently intend to hold the Meeting in person. However, depending on developments with respect to the COVID-19 pandemic, we might hold the Meeting virtually on the above date and time instead
        of in person, and attendance in person may otherwise be subject to certain restrictions of the Israeli Ministry of Health, to the extent any such restrictions are imposed. If we determine that a change to a virtual meeting format is advisable or
        required, an announcement of such change will be filed with the SEC on a Report on Form 6-K and with the ISA as promptly as practicable.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Whether or not you plan to attend the Meeting, you are urged to promptly complete, date and sign the enclosed proxy and to mail it in the enclosed envelope, which requires no postage if mailed in
        the United States. A shareholder, whose ordinary shares, New Israeli Shekels 0.01 nominal (par) value per share of the Company&#160; (&#8220;<font style="font-weight: bold;">Ordinary Shares</font>&#8221;) are registered with a member of the Tel-Aviv Stock Exchange
        Ltd. (the &#8220;<font style="font-weight: bold;">TASE</font>&#8221;), and intends to vote his or her Ordinary Shares by proxy, should deliver or mail (via registered mail) his or her completed proxy to the Company&#8217;s offices, attention: General Counsel,
        together with an ownership certificate confirming his or her ownership of the Ordinary Shares as of the record date, which certificate must be approved by a recognized financial institution, i.e. that TASE member through which he or she holds
        Ordinary Shares, as required by the Israeli Companies Regulations (Proof of Ownership of Shares for Voting at General Meeting), 2000, as amended. Such shareholder is entitled to receive the ownership certificate in a branch of the relevant TASE
        member or by mail to his or her address, if the shareholder so requests. Such a request must be made in advance for a particular securities account. Alternatively, a shareholder who holds Ordinary Shares through members of TASE may vote
        electronically via the electronic voting system of the ISA (the &#8220;<font style="font-weight: bold;">Electronic Voting System</font>&#8221;), after receiving a personal identifying number, an access code and additional information regarding this Meeting
        from the member of the TASE and after carrying out a secured identification process,&#160;up to six (6) hours before the time set for the Meeting. If applicable, a shareholder may request instructions about such electronic voting from the TASE member
        through which he or she holds the Ordinary Shares.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Execution and return of a shareholder&#8217;s proxy will not deprive such shareholder of his or her right to attend the Meeting and vote in person, and any shareholder giving a proxy has the right to
        revoke it as specified in this proxy statement.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%LCR%2%- % -%-->
      <div style="text-align: justify; line-height: 1.25;">Joint holders of Ordinary Shares should take note that, pursuant to Article 37(d) of the Articles of Association of the Company, the vote of the senior holder who tenders a vote, in person, by
        proxy, by proxy card or by electronic voting, will be accepted to the exclusion of any vote(s) of the other joint holder(s), and for this purpose seniority will be determined by the order in which the names appear in the Company&#8217;s register of
        shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">A proxy will be effective only if it is received at the Company&#8217;s office no later than twenty-four (24) hours prior to the time of the Meeting (i.e., 5:00 PM Israel time on
        September 13, 2022), or, in case of a shareholder voting electronically through the Electronic Voting System, no later than six (6) hours prior to the time of the Meeting (i.e., 11:00 AM Israel time on September 14, 2022).</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="z00a0a8565fd24b10935ad4d57615ae99">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">By Order of the Board of Directors,</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"> <br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><u>/s/ Mr. Paul Sekhri</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Paul Sekhri</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Chairman of the Board of Directors</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Holon, Israel</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">August 4, 2022</div>
            </td>
          </tr>

      </table>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">- ii -</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROXY STATEMENT</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">26 Harokmim Street, Bldg. D</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Holon, Israel</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">2022 Annual General Meeting of Shareholders</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps;">To be Held on September 14, 2022</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">This proxy statement is being furnished to the holders of ordinary shares, New Israeli Shekels (&#8220;<font style="font-weight: bold;">NIS</font>&#8221;) 0.01 nominal (par) value per share (&#8220;<font style="font-weight: bold;">Ordinary Shares</font>&#8221;) of Compugen Ltd. (&#8220;<font style="font-weight: bold;">Compugen</font>&#8221; or the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) in connection with the solicitation by the Board of Directors of
        the Company (the &#8220;<font style="font-weight: bold;">Board of Directors</font>&#8221;) of proxies for use at the Company&#8217;s 2022 Annual General Meeting of Shareholders, or at any adjournment or postponement thereof (the &#8220;<font style="font-weight: bold;">Meeting</font>&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The Meeting will be held on Wednesday, September 14, 2022, at 5:00 PM (Israel time), at the Company&#8217;s offices at 26 Harokmim Street, Bldg. D, Holon, Israel, for the following purposes:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6b851daf1f994c39a5f5004dc8dfc5e7">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To re-elect seven (7) directors to serve as members of the Board of Directors.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z13fdaec502ae4d78a034c17e400458fa">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To re-appoint Kost Forer Gabbay &amp; Kasierer (a member of Ernst &amp; Young Global), as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2022, and until the next annual general of
                the Company&#8217;s shareholders, and to authorize the Board of Directors, upon recommendation of the Company&#8217;s Audit Committee (the &#8220;<font style="font-weight: bold;">Audit Committee</font>&#8221;), to determine the remuneration thereof in accordance
                with the volume and nature of its services. </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">In addition, at the Meeting, shareholders will also have an opportunity to discuss the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2021. This
        item will not involve a vote of the shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Should changes be made to any item on the agenda for the Meeting after the publication of this proxy statement, the Company will communicate the changes to its shareholders through the publication
        of a press release, a copy of which will be filed with the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold;">SEC</font>&#8221;) on a Report on Form 6-K and with the Israeli Securities Authority (the &#8220;<font style="font-weight: bold;">ISA</font>&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">We currently intend to hold the Meeting in person. However, depending on developments with respect to the COVID-19 pandemic, we might hold the Meeting virtually on the above date and time instead
        of in person, and attendance in person may otherwise be subject to certain restrictions of the Israeli Ministry of Health, to the extent any such restrictions are imposed. If we determine that a change to a virtual meeting format is advisable or
        required, an announcement of such change will be filed with the SEC on a Report on Form 6-K and with the ISA as promptly as practicable.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">RECORD DATE AND VOTING RIGHTS</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Only holders of record of Ordinary Shares at the close of business on Tuesday, August 9, 2022, the record date for determining those shareholders eligible to vote at the Meeting, will be entitled
        to notice of and to vote at the Meeting and any postponements or adjournments thereof. At such time, each issued and outstanding Ordinary Share will be entitled to one vote upon each of the matters to be presented at the Meeting.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROXY PROCEDURE</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">A form of proxy for use at the Meeting and a return envelope for the proxy are also enclosed.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">If specified by a shareholder on the form of proxy, the Ordinary Shares represented thereby will be voted in accordance with such specification. If a choice is not specified by a shareholder with
        respect to any proposal, the form of proxy will be voted &#8220;FOR&#8221; any such proposal and in the discretion of the proxies with respect to all other matters which may properly come before the meeting and any and all adjournments thereof. On all matters
        considered at the Meeting, abstentions and broker non-votes will be treated as neither a vote &#8220;FOR&#8221; nor &#8220;AGAINST&#8221; the matter, although they will be counted in determining if a quorum is present. Broker non-votes are votes that brokers holding
        shares of record for their clients are, pursuant to applicable stock exchange or other rules, precluded from casting in respect of certain non-routine proposals because such brokers have not received specific instructions from their clients as to
        the manner in which such shares should be voted on those proposals and as to which the brokers have advised the Company that, accordingly, they lack voting authority.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: justify; line-height: 1.25;">A shareholder, whose Ordinary Shares are registered with a member of the TASE, and intends to vote his or her Ordinary Shares by proxy, should deliver or mail (via registered mail) his or her
        completed proxy to the Company&#8217;s offices, attention: General Counsel, together with an ownership certificate confirming his or her ownership of the Company&#8217;s Ordinary Shares as of the record date, which certificate must be approved by a recognized
        financial institution, i.e. that TASE member through which he or she hold their Ordinary Shares, as required by the Israeli Companies Regulations (Proof of Ownership of Shares for Voting at General Meeting), 2000, as amended. Such shareholder is
        entitled to receive the ownership certificate in a branch of the relevant TASE member or by mail to his or her address, if the shareholder so requests. Such a request must be made in advance for a particular securities account. Alternatively, a
        shareholder who holds Ordinary Shares through members of TASE may vote electronically via the electronic voting system of the ISA (the &#8220;<font style="font-weight: bold;">Electronic Voting System</font>&#8221;), after receiving a personal identifying
        number, an access code and additional information regarding this Meeting from the member of the TASE and after carrying out a secured identification process, up to six (6) hours before the time set for the Meeting. If applicable, a shareholder may
        request instructions about such electronic voting from the TASE member through which he or she holds Ordinary Shares.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Joint holders of Ordinary Shares should take note that, pursuant to Article 37(d) of the Articles of Association of the Company (the &#8220;<font style="font-weight: bold;">Articles</font>&#8221;), the vote of
        the senior holder who tenders a vote, in person, by proxy, by proxy card or by electronic voting, will be accepted to the exclusion of any vote(s) of the other joint holder(s), and for this purpose seniority will be determined by the order in which
        the names appear in the Company&#8217;s register of shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">A proxy will be effective only if it is received at the Company&#8217;s office no later than twenty-four (24) hours prior to the time of the Meeting (i.e., 5:00 PM Israel time on
        September 13, 2022), or, in case of a shareholder voting electronically through the Electronic Voting System, no later than six (6) hours prior to the time of the Meeting (i.e., 11:00 AM Israel time on September 14, 2022).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">A shareholder may revoke the authority granted by execution of his or her proxy at any time before the effective exercise thereof by: (i) filing with the Company a written notice of revocation or
        duly executed proxy bearing a later date (which revocation or new proxy will be effective only if it is received at the Company&#8217;s office no later than twenty four (24) hours prior to the time of the Meeting, as noted above); (ii) electronically
        voting through the Electronic Voting System at a later date (but no later than six (6) hours prior to the time of the Meeting); or (iii) voting in person at the Meeting. However, attendance at the Meeting will not in and of itself constitute
        revocation of proxy, and if a shareholder attends the Meeting and does not elect to vote in person, his or her proxy or electronic voting through the Electronic Voting System will not be revoked.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Proxies for use at the Meeting are being solicited by the Board of Directors mainly by mail. The Company will bear the cost for the solicitation of the proxies, including postage, printing and
        handling, and will reimburse the reasonable expenses of brokerage firms and others for forwarding material to beneficial owners of Ordinary Shares. In addition to solicitation by mail, certain of the Company&#8217;s officers, directors, employees,
        consultants and agents may solicit proxies by telephone, electronic mail or other personal contact. None of the aforementioned officers, directors, employees, consultants or agents of the Company will receive additional compensation for such
        solicitation.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">QUORUM</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Two or more shareholders present in person, by proxy or by voting through the Electronic Voting System and holding together Ordinary Shares conferring in the aggregate twenty five percent or more
        of the voting power of the Company, shall constitute a quorum at the Meeting. If within half an hour from the time set for the Meeting a quorum is not present, the Meeting shall stand adjourned to Wednesday, September 21, 2022, at the same time and
        place. At such adjourned meeting, any two shareholders present in person, by proxy or by voting through the Electronic Voting System, shall constitute a quorum.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">BENEFICIAL OWNERSHIP OF SECURITIES BY PRINCIPAL</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;SHAREHOLDERS AND MANAGEMENT</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The following table sets forth certain information as of July 31, 2022 regarding (i) persons or entities known to the Company to beneficially own more than 5% of the Company&#8217;s outstanding Ordinary
        Shares, (ii) each &#8220;office holder&#8221;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup>, as such term is defined in the Israeli Companies Law, 5759-1999 (the &#8220;<font style="font-weight: bold;">Companies Law</font>&#8221;) of the Company (the &#8220;<font style="font-weight: bold;">Office Holders</font>&#8221;)
        known to the Company to beneficially own more than 1% of the Company&#8217;s issued and outstanding Ordinary Shares (to the extent applicable); and (iii) all Office Holders as a group.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The information contained in the table below has been obtained from the Company&#8217;s records or disclosed in public filings with the SEC.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Except where otherwise indicated, and except pursuant to community property laws, we believe, based on information furnished by such owners, that the beneficial owners of the Ordinary Shares listed
        below have sole investment and voting power with respect to such Ordinary Shares.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Total &#8220;Number of Ordinary Shares Beneficially Owned&#8221; in the table below includes Ordinary Shares that may be acquired by an individual or group upon the exercise of options that are either
        currently exercisable or will become exercisable within 60&#160;days of July 31, 2022.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The shareholders listed below do not have any different voting rights from any of our other shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" class="cfttable" id="z0eb5fb10332f46d4b41c6005feb8a9f6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

          <tr>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-weight: bold;">Beneficial Owner</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number of Ordinary Shares Beneficially Owned</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Percent of Ordinary Shares Beneficially Owned<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">ARK Investment Management LLC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">9,222,415</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">10.6</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-align: justify; line-height: 1.25;">Nikko Asset Management Co., Ltd.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">6,998,382</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">8.1</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Sumitomo Mitsui Trust Holdings, Inc.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">6,998,382</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">8.1</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-align: justify; line-height: 1.25;">Brisol-Myers Squibb Company<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">4,757,058</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">5.5</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Dr. Anat Cohen-Dayag<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">992,372</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">1.13</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">%<br>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="text-align: justify; line-height: 1.25;">All Office Holders, including directors, as a group (consists of 15 persons)</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">3,165,565</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">3.53</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z92f1c0a250f34a8d99b628917589563a">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based upon 86,624,643 Ordinary Shares issued and outstanding as of July 31, 2022.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdaf90bbfe1664ec29b2c15329f15dc75">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based upon information provided by the shareholder in its Schedule 13G/A filed with the SEC on February 9, 2022. With respect to the Ordinary Shares reported in its Schedule 13G/A, ARK Investment Management LLC, or ARK, indicated as
                having (i) sole voting power with respect to 8,879,327 Ordinary Shares, (ii) shared voting power with respect to 210,870 Ordinary Shares, (iii) sole dispositive power with respect to 9,222,415 Ordinary Shares, and (iv) no shared dispositive
                power with respect to Ordinary Shares. Furthermore, in such filing ARK indicated aggregate beneficial ownership of 9,222,415 Ordinary Shares. The address of the principal business office of ARK is 3 East 28th Street, 7th Floor, New York, NY
                10016.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3368d0bae61f4864b972c745b5f5bad1" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="vertical-align: top; width: 36pt;">
                <div style="text-align: justify; text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
              </td>
              <td style="vertical-align: top; width: auto;">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Based upon information provided by the shareholder in its Schedule 13G/A filed with the SEC on February 14, 2022. With respect to the Ordinary
                  Shares reported in the Schedule 13G/A, Nikko Asset Management Americas, Inc., or Nikko, indicated as having (i) no sole voting or dispositive power with respect to Ordinary Shares, (ii) shared voting power with respect to 5,851,942
                  Ordinary Shares, and (iii) shared dispositive power with respect to 6,998,382 Ordinary Shares. Furthermore, in such filing Nikko indicated aggregate beneficial ownership of 6,998,382 Ordinary Shares. The address of the principal business
                  office of Nikko is 605 Third Avenue, 38th&#160;Floor, New York, NY 10158.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z89b965f7b1044deba49fc624440b5e21">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based upon information provided by the shareholder in its Schedule 13G/A filed with the SEC on February 4, 2022. With respect to the Ordinary Shares reported in the Schedule 13G/A, Sumitomo Mitsui Trust Holdings, Inc., or Sumitomo,
                indicated as having (i) no sole voting or dispositive power with respect to Ordinary Shares and (ii) shared voting power and dispositive power with respect to 6,998,382 Ordinary Shares. Furthermore, in such filing Sumitomo indicated
                aggregate beneficial ownership of 6,998,382 Ordinary Shares. The address of the principal business office of Sumitomo is 1-4-1 Marunouchi, Chiyoda-ku, Tokyo 100-8233, Japan.</div>
            </td>
          </tr>

      </table>
      <div>&#160;<br>
        <hr noshade="noshade" align="left" style="background-color: #000000; border: 0px; height: 1px; width: 2in; margin-left: 0pt; margin-right: auto; color: #000000;">
        <div style="text-align: justify; line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> The term &#8220;Office Holder&#8221; as defined in the Companies Law includes a director, the chief executive officer, the chief business officer, the vice chief executive officer, the deputy
          chief executive officer, any other person fulfilling or assuming any of the foregoing positions without regard to such person&#8217;s title and any manager who is directly subordinated to the chief executive officer. In addition to the current seven
          members of our Board of Directors, the Company defines an additional eight individuals to be Office Holders.</div>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z059ecea90f5a485199343aa9123117d3">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup></td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based upon information provided by the shareholder in its Form 13G filed with the SEC on November 19, 2021, and confirmation by the shareholder that such information is true and correct as of the date of our Annual Report on Form 20-F/A
                for the year ended December 31, 2021, filed with the SEC on February 28, 2022 (File No. 000-30902) (the &#8220;<font style="font-weight: bold;">2021 Form 20-F</font>&#8221;). With respect to the Ordinary Shares reported in its Schedule 13G,
                Bristol-Myers Squibb Company, or BMS, indicated as having (i) sole voting power and dispositive power with respect to 4,757,058 Ordinary Shares, and (ii) no shared voting power nor shared dispositive power with respect to Ordinary Shares.
                Furthermore, in such filing BMS indicated aggregate beneficial ownership of 4,757,058 Ordinary Shares. The address of the principal business office of BMS is 430 East 29<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>&#160;Street, New York, NY 10016.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc338695e5f574971a8c5ab89ab3a4e93">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup></td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Includes (i) 56,122 Ordinary Shares held by Dr. Cohen-Dayag, and (ii) 936,250 Ordinary Shares subject to options that are exercisable within&#160;60 days after July 31, 2022.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">For information relating to the remuneration of our five most highly compensated Office Holders with respect to the year ended December 31, 2021, please see &#8220;Item 6. Directors, Senior Management
        and Employees - B. Compensation - Individual Compensation of Covered Office Holders&#8221; in our 2021 Form 20-F.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">ITEM NO. 1</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">RE-ELECTION OF SEVEN (7) DIRECTORS</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-right: 0.3pt; line-height: 1.25; font-weight: bold;">Background</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The Articles provide that the number of directors to serve on our Board of Directors shall be no less than five (5) and no more than fourteen (14).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The Board of Directors is currently comprised of seven (7) members, all of whom have a serving term that expires at the end of the Meeting, and all of whom stand for re-election for an additional
        term of service.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Directors are generally elected at each annual general meeting of the Company&#8217;s shareholders for a term starting at such meeting and ending at the conclusion of the next annual general meeting of
        the Company&#8217;s shareholders and until his or her respective successor has been elected, or until his or her office is vacated earlier in accordance with the provisions of the Companies Law and the Articles. In accordance with our Articles, directors
        may also be appointed by our Board of Directors in between annual general meetings of the Company&#8217;s shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-right: 0.3pt; line-height: 1.25; font-weight: bold;">General</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Election</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">At the Meeting, all of the Company&#8217;s incumbent seven (7) directors are nominated for re-election. Following the recommendation of our Nomination and Corporate Governance Committee to the Board of
        Directors in accordance with Rule 5605(e) of the Nasdaq Marketplace Rules (&#8220;<font style="font-weight: bold;">Nasdaq Rules</font>&#8221;), it is proposed that Mr. Paul Sekhri, Dr. Anat Cohen-Dayag, Mr. Eran Perry, Mr. Gilead Halevy, Dr. Mathias
        Hukkelhoven (who was appointed by the Board of Directors in March, 2022 to replace Dr. Jean-Pierre Bizzari, who retired from service on the Board of Directors), Dr. Kinneret Livnat Savitzky and Mr. Sandy Zweifach be re-elected as directors. If
        re-elected, each director nominee will serve for a term ending on the date of the 2023 annual general meeting of the Company&#8217;s shareholders and until his or her respective successor has been elected, or until his or her office is vacated earlier in
        accordance with the provisions of the Companies Law and the Articles.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">In accordance with Israeli law, a nominee for service as a director must submit a declaration to the Company, prior to his or her nomination, specifying that he or she has the requisite
        qualifications to serve as a director, and the ability to devote the appropriate time to performing his or her duties as such. All candidates for re-election as directors at the Meeting have declared in writing that they possess the requisite
        skills and expertise, as well as sufficient time, to perform their duties as directors of the Company. Other than Dr. Cohen-Dayag, our President and Chief Executive Officer, none of the director nominees has any relationship with the Company.
        Accordingly, our Board of Directors determined that all of the director nominees, except for Dr. Cohen-Dayag, qualify as &#8220;independent directors,&#8221; as defined by Nasdaq Rules. In addition, in accordance with our Board of Directors&#8217; decision in 2018
        to adopt certain relief for companies whose shares are listed for trading in certain foreign stock exchanges, including the Nasdaq Stock Exchange, pursuant to which, if a nominee for service as a director meets the qualification criteria for being
        classified as an independent director in accordance with the law of the relevant foreign jurisdiction and does not have any affiliation with a &#8220;controlling shareholder&#8221; (as defined in the Companies Law) (which is not relevant in our case), the
        Audit Committee may classify him or her as independent director in accordance with the Companies Law. Accordingly, our Audit Committee classified each of our director nominees, except for Dr. Cohen-Dayag, as independent directors in accordance with
        the Companies Law.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Furthermore, each of the members of the Audit Committee is classified as &#8220;independent&#8221; as such term is defined in Rule 10A-3(b)(1) under the Exchange Act, which provides additional qualification
        criteria to the general test for independence of board and committee members under the Nasdaq Rules. Additionally, all such members are financially literate under the applicable rules and regulations of the SEC and Nasdaq Rules and each of whom is
        an audit committee financial expert, as defined by the SEC rules, and has the requisite financial experience required under the Nasdaq Rules.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The Company is not aware of any reason why any of the director nominees, if elected, would be unable to serve as a director.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The names of each director nominee, the year in which such director was first elected to the Board of Directors, the age of such director as of July 31, 2022 and his or her service as an executive
        officer of the Company or as a member of a committee of the Board of Directors are as follows:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z2c5ede9f221144f5b17ef9240a45def6">

          <tr>
            <td style="width: 25%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">Name</div>
              </div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td style="width: 10%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;"><font style="line-height: 1.25;">&#160;</font>Age</div>
              </div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td style="width: 14%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><font style="line-height: 1.25;">&#160;</font>Year of First Election</div>
              </div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 45%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">Positions</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Paul Sekhri<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)(4)</sup></div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">64</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 14%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2017</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 45%; vertical-align: middle; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Chairman of the Board of Directors (Chairman of the Nomination and Corporate Governance Committee)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: middle;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Anat Cohen-Dayag, Ph.D.</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 10%; vertical-align: middle;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">55</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2014</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: middle;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">President and Chief Executive Officer, Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Eran Perry<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)(2)(4)</sup></div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">51</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 14%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2019</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 45%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: middle;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Gilead Halevy<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)(4)</sup></div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 10%; vertical-align: middle;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">55</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2018</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: middle;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Director (Chairman of the Audit Committee)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: middle; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Mathias (Math) Hukkelhoven, Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 10%; vertical-align: middle; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">68</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 14%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2022</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 45%; vertical-align: middle; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: middle;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Kinneret Livnat Savitzky, Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)(3)(4)</sup></div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 10%; vertical-align: middle;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">55</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2018</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: middle;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Sanford (Sandy) Zweifach<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)(2)(3)(4)</sup></div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">66</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 14%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2018</div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 45%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Director (Chairman of the Compensation Committee)</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 18pt; line-height: 1.25;">____________________</div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z246849c653cc4cd4bcf532085d468b74" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 18pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(1)</font></div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Member of our Compensation Committee</font></div>
              </td>
            </tr>

        </table>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z530f78edc14e46eba338b0e3c5a45371">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">(2)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Member of our Audit Committee (and audit committee financial expert, as defined by the SEC rules, with requisite financial experience required under the applicable Nasdaq Rules)</div>
            </td>
          </tr>

      </table>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5a8a399c5f354627b691ddd807acc983" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 18pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(3)</font></div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Member of our Nomination and Corporate Governance Committee</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z18dcdc4e39b544dfbcb22a2639e694bf" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 18pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(4)</font></div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Independent Director</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">All of the Company&#8217;s incumbent directors (except for Dr. Math Hukkelhoven who was appointed by the Board of Directors in March 2022 to replace Dr. Jean-Pierre Bizzari, as mentioned above) were
        elected with the support of approximately 90% or more of our Ordinary Shares voted at the annual general meeting of the Company&#8217;s shareholders for 2021, held on September 2, 2021 (the &#8220;<font style="font-weight: bold;">2021 AGM</font>&#8221;).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Since the 2021 AGM, each current member of the Board of Directors who was previously elected at the 2021 AGM attended at least 89% of the meetings of the Board of Directors and its committees on
        which such member served during such time.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The following are brief biographies of each of the seven (7) director nominees, based upon our records and information furnished to us by them:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 28.1pt; line-height: 1.25;"><font style="font-weight: bold;">Paul Sekhri </font>joined Compugen&#8217;s Board of Directors as its Chairman in October 2017. Mr. Sekhri serves as the President and Chief
        Executive Officer of&#160;vTv Therapeutics Inc. Prior to joining vTv Therapeutics Inc., from January 2019 until April 2022, Mr. Sekhri served as the President and CEO of eGenesis, Inc. and from February 2015 through December 2018 he served as President
        and CEO of Lycera Corp. From April 2014 through January 2015, Mr. Sekhri served as Senior Vice President, Integrated Care for Sanofi. From May 2013 through March 2014, Mr. Sekhri served as Group Executive Vice President, Global Business Development
        and Chief Strategy Officer for Teva Pharmaceutical Industries Ltd. Prior to joining Teva, Mr. Sekhri spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG
        Capital. From 2004 to 2009, Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc. Previously,
        Mr. Sekhri spent four years at Novartis, as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. Mr. Sekhri also developed the Disease Area Strategy for Novartis, identifying
        those specific therapeutic areas upon which the company would focus. Mr. Sekhri&#8217;s first role at Novartis was as Global Head, Early Commercial Development. Mr. Sekhri completed graduate work in Neuroscience at the University of Maryland School of
        Medicine, where he also received his BS in Zoology. Mr. Sekhri is currently a member of the Board of Directors of vTv Therapeutics Inc., Spring Discovery, Inc., eGenesis, Inc., Veeva Systems Inc., Ipsen S.A., Chairman of the Board of Directors of
        Pharming N.V. and of Longboard Pharmaceuticals, Inc. Additionally, Mr. Sekhri is&#160;the Chairman of the Board of The Knights, and a member of the Board of The Metropolitan Opera. Mr. Sekhri is also an active member of the Patrons Council of Carnegie
        Hall, where he established the Life Sciences Council of Carnegie Hall.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 28.1pt; line-height: 1.25;"><font style="font-weight: bold;">Dr. Anat Cohen-Dayag </font>joined Compugen&#8217;s Board of Directors in February 2014. Dr. Cohen-Dayag joined Compugen in 2002 and held various
        positions. In November 2008, Dr. Cohen-Dayag was appointed as Vice President, Research and Development. In June 2009, Dr. Cohen-Dayag was appointed as co-Chief Executive Officer of Compugen and in March 2010 Dr. Cohen-Dayag was appointed as
        Compugen&#8217;s President and CEO. Prior to joining Compugen, Dr. Cohen-Dayag was head of research and development and member of the Executive Management at Mindsense Biosystems Ltd. Prior to Mindsense Biosystems Ltd., Dr. Cohen-Dayag served as a
        scientist at the R&amp;D department of Orgenics Ltd. Dr. Cohen-Dayag is a member of the Board of Directors of Gamida Cell&#160;Ltd. and Pyxis Ltd. Dr. Cohen-Dayag holds a B.Sc. in Biology from the Ben-Gurion University, Israel, and an M.Sc. in Chemical
        Immunology and a Ph.D. in Cellular Biology, both from the Weizmann Institute of Science, Israel.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 28.1pt; line-height: 1.25;"><font style="font-weight: bold;">Eran Perry </font>joined Compugen&#8217;s Board of Directors in July 2019.&#160; Eran Perry brings to Compugen over 20 years of diverse experience across
        various segments of the healthcare industry as an entrepreneur and venture capital investor as well as in general management and strategy. In 2018, Mr.&#160;Perry co-founded MII Fund &amp; Labs, a dermatology-focused venture capital fund where he also
        serves as Managing Director and Chairman of the Investment Committee. Mr. Perry is also the co-founder and board member of several pharmaceutical companies including Musli Thyropeutics, ICD Pharma, Seanergy Dermatology, Follicle Pharma and Upstream
        Bio. Mr. Perry also serves on the board of directors of MyBiotics Pharma and Noon Aesthetics. From 2006 to 2016, he served as Managing Director and Partner of Israel Healthcare Ventures (&#8220;<font style="font-weight: bold;">IHCV</font>&#8221;) and
        represented IHCV in numerous portfolio companies. Prior to IHCV, Mr. Perry was a consultant in McKinsey &amp; Company, serving clients worldwide in the pharmaceutical industry, among others. Prior to that, he was a member of the Global Marketing
        group at Novartis Oncology.&#160;Before moving to the private sector, Mr.&#160;Perry served in the Israeli Ministry of Justice. Mr. Perry holds an MBA from Columbia University, and an LL.B. in Law and a B.Sc. in Mathematics and Computer Science, both from
        Tel Aviv University.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 28.1pt; line-height: 1.25;"><font style="font-weight: bold;">Gilead Halevy </font>joined Compugen&#8217;s Board of Directors in June 2018. Mr. Halevy serves as a general partner of Kedma Capital Partners, a
        leading Israeli private equity fund, of which he is also a founding member, since 2006. Prior to establishing Kedma, Mr. Halevy served as a Director at Giza Venture Capital from 2001 to 2006, where he led investments in communication and
        information technology companies and directed Giza&#8217;s European business activities. From 1998 to 2001, Mr. Halevy practiced law at White &amp; Case LLP. Mr. Halevy was also a founding member of the White &amp; Case Israel practice group during that
        time. Mr. Halevy currently serves as chairman of Carmel Wineries, Continuity Software Ltd., Zriha Hlavin Industries Ltd. and a director of S. AL Holdings. Mr. Halevy holds a B.A. in Humanities (multidisciplinary program for exceptional students)
        and an LL.B. (Magna Cum Laude) both from the Hebrew University of Jerusalem.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-left: 28.1pt; line-height: 1.25;"><font style="font-weight: bold;">Dr. Mathias (Math) Hukkelhoven </font>joined Compugen&#8217;s Board of Directors in March 2022. Dr. Hukkelhoven has a wealth of experience in global
        regulatory affairs and drug development, evidenced by his contribution to more than 50 NCEs and hundreds of new indications and line extensions over his career to date. Dr. Hukkelhoven has participated in activities that have shaped health
        authority interactions for the industry, including serving as chairperson of the Regulatory Affairs Coordinating Committee at PhRMA, and recently as a PhRMA negotiator for the PDUFA VII negotiations with the FDA. Since his retirement from Bristol
        Myers Squibb in July 2021, Math has been a consultant for several biotech companies, R&amp;D Strategy Advisor for LianBio and Senior Advisor for McKinsey and on July 1, 2022 he joined the Board of Directors of Centessa Pharmaceuticals plc. Math
        joined Bristol Myers Squibb in March 2010 as the Senior Vice President, Global Regulatory, Safety &amp; Biometrics and was also responsible for the R&amp;D group in BMS China and the Clinical Pharmacology and Pharmacometrics group. As such, he had
        responsibility for a large part of the global Bristol Myers Squibb development organization. Since the acquisition of Celgene by Bristol Myers Squibb, he was responsible for Global Regulatory and Safety Sciences at Bristol Myers Squibb. He was
        accountable for setting regulatory strategy and driving execution of global regulatory and pharmacovigilance plans for Bristol Myers Squibb. He led the regulatory and development efforts across the product development and commercialization process
        to ensure optimal regulatory strategy and interactions at each step of the process &#8211; research and development, manufacturing, and commercialization. Prior to joining Bristol Myers Squibb, Math held the role of Chairman Portfolio Stewardship Board
        at Novartis Pharmaceuticals. From 2001 to 2009, he was the Senior Vice President, Global Head Drug Regulatory Affairs at Novartis. Math received&#160;his B.S. and Ph.D. honors degrees in Biology and Biochemistry from the University of Nijmegen, the
        Netherlands.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 28.1pt; line-height: 1.25;"><font style="font-weight: bold;">Dr. Kinneret Livnat Savitzky </font>joined Compugen&#8217;s Board of Directors in June 2018. Dr. Livnat Savitzky currently serves as a managing
        partner at Team8 and Director at Team8 Health, Partner 1 GP Ltd.&#160;&#160;Dr. Livnat Savitzky also serves on the boards of the following biotechnology or healthcare companies: Ramot (TTO of Tel-Aviv University), Nutritional Growth Solutions Ltd., DreaMed
        Diabetes Ltd., Biomica Ltd.&#160;and two portfolio companies of FutuRx. Between 2017 and 2021 she served as the CEO of FutuRx Ltd., an Israeli biotechnology accelerator established by OrbiMed Israel Partners, Johnson &amp; Johnson Innovation, Takeda
        Ventures Inc., and LEAPS, the venture arm of Bayer. From 2010 to 2016, Dr. Livnat Savitzky served as CEO of BioLineRX Ltd., a Nasdaq-listed drug development company focused on oncology and immunology. During her tenure, BioLineRX signed a strategic
        collaboration with Novartis as well as licensing agreements with Merck (MSD), Genentech and others. Prior to being appointed CEO of BioLineRX, Dr. Livnat Savitzky held various R&amp;D management positions at BioLineRX and Compugen. Dr. Livnat
        Savitzky holds a B.Sc. in Biology from The Hebrew University of Jerusalem, and an M.S.c and Ph.D. with distinction in Human Genetics from Tel Aviv University.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 28.1pt; line-height: 1.25;"><font style="font-weight: bold;">Sanford (Sandy) Zweifach </font>joined Compugen&#8217;s Board of Directors in June 2018. Mr. Zweifach is the Founder of Nuvelution Pharma, Inc. and
        since 2015 through 2019 was the Chief Executive Officer of Nuvelution Pharma, Inc. From 2010 to 2015, Mr. Zweifach served as CEO of Ascendancy Healthcare, Inc., which he also founded. He has also been a Partner at Reedland Capital Partners, a
        boutique investment bank, from 2005 to 2010, where he headed its life sciences M&amp;A and advisory efforts. From 2003 to 2005, he was CEO of Pathways Diagnostics, a biomarker development company. Mr. Zweifach was a Managing Director/CFO of Bay
        City Capital, a venture capital/merchant banking firm, specializing in the biotech and the life science industry, where he was responsible for oversight of the firm&#8217;s finance department, as well as President of the firm&#8217;s M&amp;A and financing
        division. Prior to this, he was President and CFO of Epoch Biosciences, which was acquired by Nanogen in 2004. Currently Mr. Zweifach serves as an Executive Chairman of the Board of Directors of Kaerus Bioscience, Chairman of the Board of Directors
        of Carisma Therapeutics, Inc.,&#160;Chair of the Business Advisory Board of IMIDomics, S.L. and as a member of the Board of Directors of Essa Pharma, Inc. Earlier in his career, Mr. Zweifach was a Certified Public Accountant (US) for Coopers &amp;
        Lybrand and held various investment banking positions focusing on biotech. He received his B.A. in Biology from UC San Diego and an M.S. in Human Physiology from UC Davis.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Directors&#8217; Compensation</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><u>Compensation to our Non-Executive Directors (other than the Chairman of the Board of Directors, Mr. Paul Sekhri)</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;">As approved by the Company&#8217;s shareholders on August 6, 2018, each of our non-executive directors, whether currently in office or appointed in the future, excluding the Chairman
        of the Board of Directors (each, a &#8220;<font style="font-weight: bold;">non-executive director</font>&#8221;) is entitled to the following compensation: (a) (i) an annual fee of $45,000&#160;and an additional annual amount for service as a member of each of the
        Company&#8217;s board committees (up to $2,500 for service as a member of a committee and up to $5,000 for service as a chairman of a committee); and (ii) an annual grant of options to purchase Ordinary Shares, with a one-time grant of 35,000 options in
        the first year of service (the &#8220;<font style="font-weight: bold;">Initial Option Grant</font>&#8221;) and an additional annual grant of 10,000 options in each of the following years of service (the &#8220;<font style="font-weight: bold;">Annual Option Grant</font>&#8221;).
        The&#160;grant date of each Initial Option Grant is the date of appointment for service as director, whether initially appointed by the Board of Directors or by the general meeting of the Company&#8217;s shareholders, with an exercise price equal to the
        closing price of the Ordinary Shares on the Nasdaq on the last trading day prior to the date of initial appointment to serve on the Board of Directors. The grant date of each Annual Option Grant is such date on which the Board of Directors approves
        the annual option grants to other Office Holders (provided that the service as director continues at the time of each grant), and the exercise price equals to the closing price of the Ordinary Shares on the Nasdaq on the last trading day prior to
        such Board of Directors approval. All such grants vest over a four-year period as follows: 25% of the options granted vest on the first day of the quarter one calendar year immediately following the quarter in which the options were granted, and an
        additional 6.25% of the options granted vest each quarter thereafter for the next thirty-six (36) months. Other than as described herein, both the Initial Option Grants and the Annual Option Grants are subject to the terms and conditions of the
        Company&#8217;s 2010 Share Incentive Plan, as amended (the &#8220;<font style="font-weight: bold;">2010 Plan</font>&#8221;), or any other equity-based incentive plan that the Company may adopt in the future and pursuant to which these options would be granted, and
        will expire ten years after their grant date, unless they expire earlier in accordance with the terms of the 2010 Plan.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;">Notwithstanding the terms of the relevant equity-based plan, all options granted to non-executive directors shall become fully vested immediately upon the completion of one or
        more of the following events, whether by way of a consolidation, merger or reorganization of the Company or otherwise: (a) a sale of all or substantially all of Company&#8217;s issued share capital or assets to any other company, entity, person or a
        group of persons, or (b) the acquisition of more than 50% of the Company&#8217;s equity or voting power by any shareholder or group of shareholders. Further, notwithstanding the terms of the relevant equity-based plan, all options granted which shall be
        vested as of the date of final termination of office as a non-executive director of the Company may be exercised within one year following such termination of office. To the extent legally available and applicable, such options will be granted to
        the non-executive directors through a trustee under Section 102 of the Israel Income Tax Ordinance [New Version], 5721-1961, under the capital gains route.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">At the Company&#8217;s 2020 Annual General Meeting of Shareholders (the &#8220;<font style="font-weight: bold;">2020 AGM</font>&#8221;), our shareholders approved, following the approvals of the Company&#8217;s
          compensation committee (the &#8220;<font style="font-weight: bold;">Compensation Committee</font>&#8221;) and the Board of Directors, and consistent with the Company&#8217;s compensation policy, as most recently amended at the 2020 AGM (the &#8220;<font style="font-weight: bold;">Compensation Policy</font>&#8221;), that instead of an Annual Option Grant, the Compensation Committee and the Board of Directors may issue to all non-executive directors RSUs or other equity awards which are not options (&#8220;<font style="font-weight: bold;">Other Equity</font>&#8221;), in which case the Annual Option Grant of 10,000 options shall be adjusted to 5,000 units of Other Equity awards, provided, that with respect to an annual equity grant that combines both types of
          equity awards (<font style="font-style: italic;">i.e.</font>, options and Other Equity), such grant shall be adjusted, on a pro rata basis, to give effect to the relative portion of each type of equity awarded (for illustration purposes, if the
          Compensation Committee and Board of Directors approve the grant of 4,000 RSUs to the non-executive directors, the relevant annual equity grant will be comprised of a total of 6,000 units, out of which 4,000 will be RSUs and 2,000 will be
          options). The provisions relating to vesting, acceleration and exercise period applicable to options, as specified above, shall apply to Other Equity that may be granted,&#160;<font style="font-style: italic;">mutatis mutandis</font>.</div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;">In accordance with the above-mentioned terms, our Compensation Committee and Board of Directors, in their separate meetings held on March 21, 2022, and March 24, 2022,
        respectively, resolved to grant to each of our non-executive directors (including Mr. Paul Sekhri, as specified below, but excluding Dr. Mathias Hukkelhoven who was granted with 35,000 options upon his appointment on March 1, 2022), 10,000 options
        with an exercise price of $3.24 per Ordinary Share. Such grant is in line with the Compensation Policy and does not require shareholder approval.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><u>Compensation to Mr. Paul Sekhri, the Company&#8217;s Chairman of the Board of Directors, a Non-Executive Director</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;">Subject to his re-election for service as director at the Meeting, Mr. Paul Sekhri is entitled to an annual cash fee in the amount of $150,000 for his service as the Company&#8217;s
        non-executive chairman of the Board of Directors (with no fees for participation in meetings of the Board of Directors and its committees).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;">In addition, in October 2017, Mr. Sekhri was granted with a one-time grant of options to purchase 500,000 Ordinary Shares, all of which are vested as of the date of this proxy
        statement. These options are subject to the terms and conditions applicable to options granted under the 2010 Plan, and will expire ten years after their grant date, unless they expire earlier in accordance with the terms of the 2010 Plan. The
        acceleration provisions applicable to options granted to other non-executive directors specified above apply to the options granted to Mr. Sekhri.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">At the 2020 AGM, our shareholders approved, following the approvals of the Compensation Committee and the Board of Directors, and consistent with our Compensation Policy, that Mr. Sekhri, in his
          role as the non-executive Chairman of the Board of Directors, shall be entitled to an annual option grant of 10,000 options to purchase Ordinary Shares each year (the &#8220;<font style="font-weight: bold;">Chairman&#8217;s Annual Option Grant</font>&#8221;),
          starting from 2020 and for each of the following years of service, similar to the terms of the Annual Option Grant to the other non-executive directors as specified above.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Furthermore, as approved for the other non-executive directors, instead of the Chairman&#8217;s Annual Option Grant, the Compensation Committee and the Board of Directors may issue to Mr. Sekhri Other
          Equity, in which case the Chairman&#8217;s Annual Option Grant of 10,000 options shall be adjusted to 5,000 units of Other Equity awards, provided, that with respect to an annual equity grant that combines both types of equity awards, such grant shall
          be adjusted, on a pro rata basis, to give effect to the relative portion of each type of equity awarded as specified above with respect to other non-executive directors. The provisions relating to vesting, acceleration and exercise period
          applicable to the options, as specified above, shall apply to Other Equity that may be granted as set forth above,&#160;<font style="font-style: italic;">mutatis mutandis</font>.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">In accordance with the above-mentioned terms, our Compensation Committee and Board of Directors, in their separate meetings held on March 21, 2022, and March 24, 2022, respectively, resolved to
          grant Mr. Paul Sekhri 10,000 options with an exercise price of $3.24 per Ordinary Share. Such grant is in line with the Compensation Policy and does not require shareholder approval.</div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;">For more information relating to the compensation paid to our directors, including insurance coverage, indemnification and exemption, see &#8220;Item 6. Directors, Senior Management
        and Employees - B. Compensation&#8221; in our 2021 Form 20-F.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;">If re-elected, in consideration for their service, our director nominees shall be entitled to the compensation specified herein.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">It is proposed that the following resolution be adopted at the Meeting:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 17pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">RESOLVED</font> that each of Mr. Paul Sekhri, Dr. Anat Cohen-Dayag, Mr. Eran Perry, Mr. Gilead Halevy, Dr. Mathias Hukkelhoven, Dr. Kinneret
        Livnat Savitzky and Mr. Sandy Zweifach be, and he or she is hereby, re-elected to serve as a member of the Board of Directors of the Company to hold office until immediately following the annual general meeting of the Company&#8217;s shareholders for
        2023 and until his or her respective successor has been elected, or until his or her office is vacated earlier in accordance with the provisions of the Companies Law and the Articles.&#8221;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Election of each of the director nominees will be voted upon separately at the Meeting.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-right: 0.3pt; line-height: 1.25; font-weight: bold;">Required Vote</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">An affirmative vote of a majority of the Ordinary Shares represented and voting on this proposal at the Meeting in person, by proxy or by voting through the Electronic Voting System, is required
        for the approval of the re-election of each of the above director nominees.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">The Board of Directors recommends that the shareholders vote &#8220;FOR&#8221; the proposed resolution.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">ITEM NO. 2</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">RE-APPOINTMENT OF INDEPENDENT AUDITOR</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Background</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The Companies Law and our Articles provide that an independent auditor of the Company shall be appointed at the annual general meeting of the Company&#8217;s shareholders.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">General</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The Company&#8217;s current independent registered public accounting firm, Kost Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global (&#8220;<font style="font-weight: bold;">KFGK</font>&#8221;), is
        hereby being nominated for re-appointment as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2022, and until the next annual general meeting of the Company&#8217;s shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">KFGK has served as the Company independent auditor since 2002 and has no relationship with the Company or with any affiliate of the Company except as auditor, tax consultant and as a provider of
        other consultancy services.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">As a result of the combined provisions of the Israeli law, the Articles and the Sarbanes-Oxley Act of 2002, the appointment of the independent registered public accounting firm requires the
        approval of the shareholders of the Company, and its remuneration requires the approval of the Board of Directors, following approval and recommendation by the Audit Committee. The Audit Committee and the Board of Directors have reviewed, and are
        satisfied with, the performance of KFGK, and have approved and are recommending to shareholders to approve their re-appointment as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December 31, 2022, and until
        the next annual general meeting of the Company&#8217;s shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The Audit Committee&#8217;s policy is to pre-approve all audit and non-audit services provided by the Company&#8217;s independent registered public accounting firm, KFGK.&#160;These services may include audit
        services, tax services and other consulting services.&#160;Additional services may be pre-approved by the Audit Committee on an individual basis.&#160;Once services have been pre-approved, the Company&#8217;s independent registered public accounting firm and
        management then report to the Audit Committee on a periodic basis regarding the extent of services actually provided in accordance with the applicable pre-approval, and regarding the fees for the services performed.&#160;Such fees for 2021 and 2020 were
        pre-approved by the Audit Committee in accordance with these procedures.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">The following table presents the aggregate amounts of fees paid or to be paid by the Company to KFGK for the services rendered in the fiscal years ended December 31, 2021 and 2020:</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" align="center" class="cfttable" id="z6fdc30dd99954f43a809a1e4430a171c" style="width: 70%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 70%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;"><font style="line-height: 1.25;"> </font></div>
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">2021</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;"><font style="line-height: 1.25;"> </font></div>
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">2020</div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Audit Fees</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">133,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">133,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 70%;">
              <div style="text-align: justify; line-height: 1.25;">Audit Related Fees</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%;">
              <div style="line-height: 1.25;">25,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%;">
              <div style="line-height: 1.25;">75,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Tax Fees</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">4,500</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">4,500</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 70%;">
              <div style="text-align: justify; line-height: 1.25;">All Other Fees</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%;">
              <div style="line-height: 1.25;">2,500</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%;">
              <div style="line-height: 1.25;">2,500</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 70%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 2.85pt; line-height: 1.25; font-weight: bold;">Total</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">165,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 12%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">215,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;Audit Fees&#8221; are fees for professional services rendered by our principal accountant in connection with the integrated audit (including review of internal control over financial reporting) of our
        consolidated annual financial statements and review of our unaudited interim financial statements;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;Audit Related Fees&#8221; are fees for professional services rendered by our principal accountant in connection with the audit and other assignments, including consultancy and consents with respect to
        an underwritten public offering and related prospectus supplements filed with the SEC;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;Tax Fees&#8221; are fees for services rendered by our principal accountant in connection with tax compliance, tax advice and tax planning which in years 2021 and 2020 were consultancy relating to
        withholding tax on payments to foreign suppliers and annual Israeli tax reports; and</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;All Other Fees&#8221; are fees for other consulting services rendered by our principal accountant to us.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">10</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">&#160;<font style="font-weight: bold;">It is proposed that the following resolution be adopted at the Meeting:</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 0.3pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">RESOLVED</font>, that Kost Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global, be, and hereby is, re-appointed as the Company&#8217;s
        independent registered public accounting firm for the fiscal year ending December 31, 2022, and until the next annual general meeting of the Company&#8217;s shareholders, and to authorize the Board of Directors, upon recommendation of the Audit
        Committee, to determine the remuneration thereof in accordance with the volume and nature of its services.&#8221;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 0.3pt; line-height: 1.25; font-weight: bold;">Required Vote</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The affirmative vote of a majority of the Ordinary Shares represented and voting on this proposal at the Meeting in person, by proxy or through the Electronic Voting System, is required for the
        approval of the above resolution.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">The Board of Directors recommends that the shareholders vote &#8220;FOR&#8221; the proposed resolution.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-variant: small-caps; font-weight: bold;">DISCUSSION REGARDING THE COMPANY&#8217;S CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR 2021</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">At the Meeting, you will also have an opportunity to discuss the consolidated financial statements of the Company for the fiscal year ended December 31, 2021.&#160; <font style="font-weight: bold;">This
          item will not involve a vote of the shareholders.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Our 2021 consolidated financial statements, as well as our 2021 Form 20-F for the year ended December 31, 2021, as amended (filed with the SEC on February 28, 2022), may be viewed on our website at
        https://ir.cgen.com/overview/default.aspx, through the EDGAR website of the SEC at www.sec.gov, through the Israeli Securities Authority&#8217;s electronic filing system at http://www.magna.isa.gov.il, or through the website of the TASE at
        http://maya.tase.co.il. None of the audited consolidated financial statements, 2021 Form 20-F or the contents of our website forms part of the proxy solicitation material.</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="z627956b168384255a4f0f955fd2f69c8">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">By Order of the Board of Directors,</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><u>/s/ Paul Sekhri</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Paul Sekhri</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Chairman of the Board of Directors</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Holon, Israel</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">August 4, 2022</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">11</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;">
        <div id="DSPFPageHeader">
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
        </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">FORM OF PROXY CARD</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">ANNUAL GENERAL MEETING OF SHAREHOLDERS</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">SEPTEMBER 14, 2022</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25;">The undersigned shareholder(s) hereby appoint(s) Anat Cohen-Dayag and Eran Ben Dor, or any one of them, as proxies, each with the power to appoint her or his substitute, and hereby authorizes
          them to represent and to vote as designated on the reverse side of this Proxy, all of the ordinary shares, New Israeli Shekels 0.01 nominal (par) value per share (the &#8220;<font style="font-weight: bold;">Ordinary Shares</font>&#8221;) of Compugen Ltd.
          (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) that the shareholder(s) is/are entitled to vote at the Annual General Meeting of Shareholders of the Company to be held at 5:00 p.m. (Israel time), on Wednesday, September 14, 2022, at the
          offices of the Company, 26 Harokmim Street, Bldg. D, Holon, Israel and any adjournment or postponement thereof (the &#8220;<font style="font-weight: bold;">Meeting</font>&#8221;).</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS DIRECTED BY THE SHAREHOLDER(S).&#160; IF NO SUCH DIRECTIONS ARE MADE, THIS PROXY WILL BE VOTED &#8220;FOR&#8221; ALL PROPOSALS AND IN THE
          DISCRETION OF THE PROXIES WITH RESPECT TO ALL OTHER MATTERS WHICH MAY PROPERLY COME BEFORE THE MEETING OR ANY AND ALL ADJOURNMENTS THEREOF.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;(Continued and to be signed on the reverse side)</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">ANNUAL GENERAL MEETING OF SHAREHOLDERS OF</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">SEPTEMBER 14, 2022</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25;">Please complete, sign, date and mail your proxy card in the envelope provided as soon as possible</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25;">_________________________________________________________________________</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; ALL PROPOSALS.</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE &#9746;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">_________________________________________________________________________</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <table cellspacing="0" cellpadding="3" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="z435cbf18d8574adc9ffc1383aea5ddb6">

            <tr>
              <td style="width: 70.61%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-indent: -27pt; margin-left: 27pt; text-align: justify;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160; To re-elect each of the seven (7) directors specified below to serve as a member of the Board of Directors of the Company to hold office until immediately
                  following the annual general meeting of the Company&#8217;s shareholders for 2023 and until his or her respective successor has been elected, or until his or her office is vacated earlier in accordance with the provisions of the Israeli
                  Companies Law, 5759-1999 and the Articles of Association of the Company</div>
              </td>
              <td style="width: 3.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
              <td style="width: 8.16%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">FOR</div>
              </td>
              <td style="width: 9.01%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">AGAINST</div>
              </td>
              <td style="width: 8.83%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">ABSTAIN</div>
              </td>
            </tr>
            <tr>
              <td style="width: 70.61%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: justify; margin-left: 42.55pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Paul Sekhri</div>
              </td>
              <td style="width: 3.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
              <td style="width: 8.16%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
              <td style="width: 9.01%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
              <td style="width: 8.83%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 70.61%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: justify; margin-left: 42.55pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Anat Cohen-Dayag, Ph.D.</div>
              </td>
              <td style="width: 3.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
              <td style="width: 8.16%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
              <td style="width: 9.01%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
              <td style="width: 8.83%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 70.61%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: justify; margin-left: 42.55pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Eran Perry</div>
              </td>
              <td style="width: 3.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
              <td style="width: 8.16%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
              <td style="width: 9.01%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
              <td style="width: 8.83%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 70.61%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: justify; margin-left: 42.55pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Gilead Halevy</div>
              </td>
              <td style="width: 3.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
              <td style="width: 8.16%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
              <td style="width: 9.01%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
              <td style="width: 8.83%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 70.61%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: justify; margin-left: 42.55pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Mathias Hukkelhoven, Ph.D.</div>
              </td>
              <td style="width: 3.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
              <td style="width: 8.16%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
              <td style="width: 9.01%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
              <td style="width: 8.83%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 70.61%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: justify; margin-left: 42.55pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Kinneret Livnat Savitzky, Ph.D.</div>
              </td>
              <td style="width: 3.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
              <td style="width: 8.16%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
              <td style="width: 9.01%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
              <td style="width: 8.83%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 70.61%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: justify; margin-left: 42.55pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Sanford (Sandy) Zweifach</div>
              </td>
              <td style="width: 3.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
              <td style="width: 8.16%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
              <td style="width: 9.01%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
              <td style="width: 8.83%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 70.61%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
              <td style="width: 3.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
              <td style="width: 8.16%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
              <td style="width: 9.01%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
              <td style="width: 8.83%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#160;</td>
            </tr>
            <tr>
              <td style="width: 70.61%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
                <div style="text-indent: -27pt; margin-left: 27pt; text-align: justify;">2.&#160;&#160;&#160;&#160;&#160;&#160; To re-appoint Kost Forer Gabbay &amp; Kasierer (a member of Ernst &amp; Young Global), as the independent registered public accounting firm of the Company for
                  the fiscal year ending December 31, 2022, and until the next annual general meeting of the Company&#8217;s shareholders, and to authorize the Board of Directors, upon recommendation of the Audit Committee, to determine the remuneration of Kost
                  Forer Gabbay &amp; Kasierer (a member of Ernst &amp; Young Global), in accordance with the volume and nature of its services.</div>
              </td>
              <td style="width: 3.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
              <td style="width: 8.16%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">FOR</div>
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
              <td style="width: 9.01%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">AGAINST</div>
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
              <td style="width: 8.83%; vertical-align: top; border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">ABSTAIN</div>
                <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25;">To change the address on your account, please check the box at right and indicate your new address in the address space above.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#9744;</div>
        <div style="text-align: justify; margin-right: 1.3pt; line-height: 1.25;"><br>
          Please note that changes to the registered name(s) on the account may not be submitted via this method.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25;">Signature of Shareholder _______________________________&#160; Date ______________ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25;">Signature of Shareholder _______________________________&#160; Date ______________ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">NOTE:&#160; </font>Please sign exactly as your name or names appear on the Proxy Statement.&#160; When Ordinary Shares are held jointly, each holder should sign. When
          signing as executor, administrator, attorney, trustee or guardian, please give full title as such.&#160; If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership,
          please sign in partnership name by authorized person.</div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <br>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !/ )0# 2(  A$! Q$!_\0
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M4*DZ?P.P&?H.C:?H&F1:?I%K':VD7W8T'?N3ZGWK0HHJ6VW=@%%%%( HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
